Impel NeuroPharma is a Seattle-based company developing intranasal drug treatments for central nervous system (CNS) disorders. Impel has developed a novel drug delivery platform, the POD technology, that administers drug to the deep nasal cavity to improve the brain distribution of many drugs. Impel’s proprietary (POD) device technology enables entirely new categories of drugs, including biologics, to be delivered to the central nervous system using a cost-effective, disposable, non-invasive intranasal drug delivery device.

The goal at Impel is simple: we want to develop the next generation of therapeutics for central nervous system (CNS) disorders. Patients with CNS disorders are vastly underserved by current therapeutics and we are working hard to change that. Impel has built the POD drug delivery platform to allow entire classes of molecules to reach the brain that never could before. Impel has expanded its scope to both partnership with pharmaceutical companies and the development of our own drug products compatible with the POD platform. We take a comprehensive approach to development and design considering patient comfort, regulatory approval pathways, and cost effectiveness. Treatments currently under development include therapies for migraine, Alzheimer’s disease, Parkinson’s disease, and pain relief

Show more
TypePrivate
HQSeattle, US
Founded2008
Size (employees)42 (est)
Websiteimpelnp.com
Impel NeuroPharma was founded in 2008 and is headquartered in Seattle, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Impel NeuroPharma

John Hoekman

John Hoekman

Co-Founder and CSO
Jon Congleton

Jon Congleton

President & CEO
Stephen Shrewsbury

Stephen Shrewsbury

Chief Medical Officer
Lynn Gold

Lynn Gold

Senior VP of Regulatory
Michael Malafronte

Michael Malafronte

VP of Quality Assurance
Meghan Swardstrom

Meghan Swardstrom

VP of Clinical Operations
Show more

Impel NeuroPharma Office Locations

Impel NeuroPharma has an office in Seattle
Seattle, US (HQ)
915 E Pine St
Show all (1)
Report incorrect company information

Impel NeuroPharma Financials and Metrics

Summary Metrics

Founding Date

2008

Impel NeuroPharma total Funding

$40.6 m

Impel NeuroPharma latest funding size

$36 m

Time since last funding

2 years ago

Impel NeuroPharma investors

Impel NeuroPharma's latest funding round in December 2016 was reported to be $36 m. In total, Impel NeuroPharma has raised $40.6 m
Show all financial metrics
Report incorrect company information

Impel NeuroPharma Company Life and Culture

Report incorrect company information